Literature DB >> 30030491

Biomarker challenges for immune checkpoint inhibitors in urothelial carcinoma.

Tom Powles1, Laura Morrison2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30030491     DOI： 10.1038/s41585-018-0056-3

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders.

Authors:  Francesco Pierconti; Maria Rosaria Raspollini; Maurizio Martini; Luigi Maria Larocca; Pier Francesco Bassi; Riccardo Bientinesi; Gianna Baroni; Andrea Minervini; Guido Petracco; Giacomo Maria Pini; Carlo Patriarca
Journal:  Virchows Arch       Date:  2020-02-07       Impact factor: 4.064

Review 2.  Molecular and histopathology directed therapy for advanced bladder cancer.

Authors:  Constantine Alifrangis; Ursula McGovern; Alex Freeman; Thomas Powles; Mark Linch
Journal:  Nat Rev Urol       Date:  2019-07-09       Impact factor: 14.432

3.  A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.

Authors:  Ali Raza Khaki; Ang Li; Leonidas N Diamantopoulos; Natalie J Miller; Lucia Carril-Ajuria; Daniel Castellano; Ivan De Kouchkovsky; Vadim Koshkin; Joseph Park; Ajjai Alva; Mehmet A Bilen; Tyler Stewart; Victor Santos; Neeraj Agarwal; Jayanshu Jain; Yousef Zakharia; Rafael Morales-Barrera; Michael Devitt; Ariel Nelson; Christopher J Hoimes; Evan Shreck; Benjamin A Gartrell; Alex Sankin; Abhishek Tripathi; Roubini Zakopoulou; Aristotelis Bamias; Alejo Rodriguez-Vida; Alexandra Drakaki; Sandy Liu; Vivek Kumar; Mark P Lythgoe; David J Pinato; Jure Murgic; Ana Fröbe; Monika Joshi; Pedro Isaacsson Velho; Noah Hahn; Lucia Alonso Buznego; Ignacio Duran; Marcus Moses; Pedro Barata; Matthew D Galsky; Guru Sonpavde; Evan Y Yu; Veena Shankaran; Gary H Lyman; Petros Grivas
Journal:  Eur Urol Oncol       Date:  2021-01-07

4.  Deficiency of Mettl3 in Bladder Cancer Stem Cells Inhibits Bladder Cancer Progression and Angiogenesis.

Authors:  Ganping Wang; Yarong Dai; Kang Li; Maosheng Cheng; Gan Xiong; Xiaochen Wang; Shuang Chen; Zhi Chen; Jianwen Chen; Xiuyun Xu; Rong-Song Ling; Liang Peng; Demeng Chen
Journal:  Front Cell Dev Biol       Date:  2021-02-18

5.  Negative Effects of Stromal Neutrophils on T Cells Reduce Survival in Resectable Urothelial Carcinoma of the Bladder.

Authors:  Meihua Yang; Bo Wang; Weibin Hou; Hao Yu; Bingkun Zhou; Wenlong Zhong; Zhuowei Liu; Jinqing Li; Hong Zeng; Cheng Liu; Haide Qin; Tianxin Lin; Jian Huang
Journal:  Front Immunol       Date:  2022-03-21       Impact factor: 7.561

Review 6.  Management of Patients with Metastatic Bladder Cancer in the Real-World Setting from the Multidisciplinary Team: Current Opinion of the SOGUG Multidisciplinary Working Group.

Authors:  Aránzazu González-Del-Alba; Antonio José Conde-Moreno; Ana M García Vicente; Pilar González-Peramato; Estefanía Linares-Espinós; Miguel Ángel Climent
Journal:  Cancers (Basel)       Date:  2022-02-23       Impact factor: 6.639

7.  Development of Tumor Mutation Burden-Related Prognostic Model and Novel Biomarker Identification in Stomach Adenocarcinoma.

Authors:  Min Fu; Yongbiao Huang; Xiaohong Peng; Xiaoyu Li; Na Luo; Wenjun Zhu; Feng Yang; Ziqi Chen; Shengling Ma; Yuanyuan Zhang; Qianxia Li; Guangyuan Hu
Journal:  Front Cell Dev Biol       Date:  2022-03-23

Review 8.  Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.

Authors:  Dong-Rui Wang; Xian-Lin Wu; Ying-Li Sun
Journal:  Signal Transduct Target Ther       Date:  2022-09-19

9.  Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.

Authors:  Ali Raza Khaki; Ang Li; Leonidas N Diamantopoulos; Mehmet A Bilen; Victor Santos; John Esther; Rafael Morales-Barrera; Michael Devitt; Ariel Nelson; Christopher J Hoimes; Evan Shreck; Hussein Assi; Benjamin A Gartrell; Alex Sankin; Alejo Rodriguez-Vida; Mark Lythgoe; David J Pinato; Alexandra Drakaki; Monika Joshi; Pedro Isaacsson Velho; Noah Hahn; Sandy Liu; Lucia Alonso Buznego; Ignacio Duran; Marcus Moses; Jayanshu Jain; Jure Murgic; Praneeth Baratam; Pedro Barata; Abhishek Tripathi; Yousef Zakharia; Matthew D Galsky; Guru Sonpavde; Evan Y Yu; Veena Shankaran; Gary H Lyman; Petros Grivas
Journal:  Cancer       Date:  2019-12-12       Impact factor: 6.921

10.  APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer.

Authors:  Divya Natesan; Li Zhang; Henry J Martell; Tanya Jindal; Patrick Devine; Bradley Stohr; Carlos Espinosa-Mendez; James Grenert; Jessica Van Ziffle; Nancy Joseph; Sarah Umetsu; Courtney Onodera; Michelle Turski; Emily Chan; Arpita Desai; Rahul Aggarwal; Anthony Wong; Sima Porten; Jonathan Chou; Terence Friedlander; Lawrence Fong; Eric J Small; Alejandro Sweet-Cordero; Vadim S Koshkin
Journal:  Front Oncol       Date:  2022-03-07       Impact factor: 6.244
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.